http://www.readimpact.com Advancing the business of biotechnology and life sciences Thu, 05 Aug 2010 12:53:28 +0000 http://backend.userland.com/rss092 en IMAF: First Money In Part 2: Entrepreneurs and Investments Entrepreneurs interested in the Inception Micro Angel Fund (IMAF) for start-up money should not be influenced by the geographical names, Triad, East, Western, Charlotte, Triangle and, soon, Coastal. “Geography doesn’t play the role it used to,” Tim Janke, IMAF executive director, said. “The ... http://www.readimpact.com/?p=365 IMAF: First Money In Part 1: The Model and Membership Providing seed-stage funding, the first money into a start-up company, is probably the riskiest type of investing. Tim Janke, executive director of the Inception Micro Angel Fund (IMAF), emphasizes that the first round of independent financing is not only risky ... http://www.readimpact.com/?p=362 Novozymes: From a Petro to a Bio Society According to the Biotechnology Industry Organization (BIO), bio-based products have the potential to replace 10 percent of US oil imports, significantly reduce CO2 emissions, create new revenue streams for US farmers and provide clean tech jobs in rural areas. A study released ... http://www.readimpact.com/?p=356 For Durham-based Tranzyme Pharma, the past year has been successful. Highlights include entering into a broad drug discovery partnership with Bristol-Myers Squibb and, most recently, a licensing agreement with Norgine B.V., a European specialty pharmaceutical company, for the exclusive rights to develop and commercialize Tranzyme’s novel ghrelin agonist, ulimorelin (TZP-101) ... http://www.readimpact.com/?p=352 After eight years in business, Wilmington Pharmaceuticals is successfully executing a business model that transforms existing drugs into fast disintegrating formulations. They capitalize on off-patent formulations or partnerships with a drug’s original developers.  “Like most entrepreneurial ideas, it started by tossing ideas around with friends in the industry and friends who ... http://www.readimpact.com/?p=347 SBTDC- Navigating Capital Resources Capital resources are the biggest challenge to any young company, says Paul Ulanch, director of technology development and commercialization for the Small Business Technology Development Center. Ulanch’s team offers counseling and support mostly to tech companies to help them navigate the options of early stage funding options.  “Clients ... http://www.readimpact.com/?p=345 Get on the Radar: NCBC and CED  The global recession may be receding, but predictions are that economic struggles may continue for the biotech and life science sector into 2011. For young companies, says Yonnie Butler, director of business development for the NC Biotechnology Center, the advice is to do ... http://www.readimpact.com/?p=326 BioNetwork, the NC Community College’s specialized training program for the biotechnology and pharmaceutical industries, is taking on the New Year with the launch of a new website, a new Career Launch Pad and a new green initiative. The goal is to stimulate workforce training not only in biotechnology and life ... http://www.readimpact.com/?p=323 Kenaf Opens Markets for Two NC Companies Growing to heights of 12 to 14 feet in less than six months, kenaf, a member of the hibiscus family, is fast growing, requires few herbicides and fertilizers and converts greenhouse gases in the environment at rate that rivals the rain forests.  The plant has ... http://www.readimpact.com/?p=319 We've started a new electronic supplement to Impact- an eFeature. While I'm on the wait for our web support to set up an archive section on our site, I'd thought I'd post our first two articles to the blog. If you're interested in receiving the eFeature, send an email to ... http://www.readimpact.com/?p=315